Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
7 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Actuate Therapeutics, Inc.’s names, not what it holds today.
Patents granted
7
7 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 4 in 2024 and none in 2023
Applications published
13
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry4
Pharmaceuticals3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Actuate Therapeutics Inc. its own name
named as the applicant on its applications, in US
13 publishedACTUATE THERAPEUTICS INC. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Nov 19, 2024 | 12,145,943 | Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | Organic fine chemistry | ACTUATE THERAPEUTICS INC. |
| Oct 15, 2024 | 12,116,374 | Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | Organic fine chemistry | ACTUATE THERAPEUTICS INC. |
| Sep 10, 2024 | 12,083,098 | Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors | Pharmaceuticals | ACTUATE THERAPEUTICS INC. |
| May 14, 2024 | 11,980,607 | Methods of treating malignant lymphoproliferative disorders | Pharmaceuticals | ACTUATE THERAPEUTICS INC. |
| Nov 29, 2022 | 11,510,904 | Methods of treating malignant lymphoproliferative disorders | Pharmaceuticals | ACTUATE THERAPEUTICS INC. |
| Aug 9, 2022 | 11,407,759 | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | Organic fine chemistry | ACTUATE THERAPEUTICS INC. |
| Oct 5, 2021 | 11,136,334 | Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | Organic fine chemistry | ACTUATE THERAPEUTICS INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 23, 2025 | 2025/0325517 | ORAL DOSAGE FORMS OF ELRAGLUSIB | Pharmaceuticals | Actuate Therapeutics Inc. |
| Apr 10, 2025 | 2025/0115616 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | Organic fine chemistry | Actuate Therapeutics Inc. |
| Apr 10, 2025 | 2025/0115615 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | Organic fine chemistry | Actuate Therapeutics Inc. |
| Nov 7, 2024 | 2024/0366563 | METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERS | Pharmaceuticals | Actuate Therapeutics Inc. |
| Apr 27, 2023 | 2023/0126700 | METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERS | Pharmaceuticals | Actuate Therapeutics Inc. · patent 11,980,607 granted from it |
| Mar 2, 2023 | 2023/0062278 | COMPOUNDS FOR THE TREATMENT OF MYELOFIBROSIS | Pharmaceuticals | Actuate Therapeutics Inc. |
| Nov 3, 2022 | 2022/0348591 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | Organic fine chemistry | Actuate Therapeutics Inc. · patent 12,116,374 granted from it |
| Feb 3, 2022 | 2022/0034766 | IMMUNOHISTOCHEMICAL STAINING FOR GSK-3 | Measurement | Actuate Therapeutics Inc. |
| Jan 13, 2022 | 2022/0009939 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | Organic fine chemistry | Actuate Therapeutics Inc. · patent 12,145,943 granted from it |
| Jul 29, 2021 | 2021/0228546 | METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERS | Pharmaceuticals | Actuate Therapeutics Inc. · patent 11,510,904 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2 · Organic fine chemistry 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.